

ARTICLE

OPEN



Unveiling the relationship between WWOX and BRCA1 in mammary tumorigenicity and in DNA repair pathway selection

Tirza Bidany-Mizrahi^{1,4}, Aya Shweiki^{1,4}, Kian Maroun¹, Lina Abu-Tair¹, Bella Mali² and Rami I. Aqeilan^{1,3}✉

© The Author(s) 2024

Breast cancer is the leading cause of cancer-related deaths in women worldwide, with the basal-like or triple-negative breast cancer (TNBC) subtype being particularly aggressive and challenging to treat. Understanding the molecular mechanisms driving the development and progression of TNBC is essential. We previously showed that WW domain-containing oxidoreductase (WWOX) is commonly inactivated in TNBC and is implicated in the DNA damage response (DDR) through ATM and ATR activation. In this study, we investigated the interplay between WWOX and BRCA1, both frequently inactivated in TNBC, on mammary tumor development and on DNA double-strand break (DSB) repair choice. We generated and characterized a transgenic mouse model (*K14-Cre;Brca1^{f/f}; Wwox^{f/f}*) and observed that mice lacking both WWOX and BRCA1 developed basal-like mammary tumors and exhibited a decrease in 53BP1 foci and an increase in RAD51 foci, suggesting impaired DSB repair. We examined human TNBC cell lines harboring wild-type and mutant BRCA1 and found that WWOX expression promoted NHEJ repair in cells with wild-type BRCA1. Our findings suggest that WWOX and BRCA1 play an important role in DSB repair pathway choice in mammary epithelial cells, underscoring their functional interaction and significance in breast carcinogenesis.

Cell Death Discovery (2024)10:145; <https://doi.org/10.1038/s41420-024-01878-8>

INTRODUCTION

Breast cancer is the most common malignancy in women and the second leading cause of death [1, 2]. Triple-negative breast cancer subtype (TNBC) is a heterogeneous disease characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and wild-type human epidermal growth factor receptor 2 (HER2) with no amplification or overexpression. It is the most aggressive breast cancer subtype and known to exhibit poor prognosis due to its lack of targetable receptors. Basal-like breast cancers (BLBCs) represent a subset of about 70% of TNBCs [3]. TNBC is typically observed (75%) in women who carry a mutation in the Breast cancer type 1 susceptibility protein, *BRCA1*, gene [4]. Hereditary and sporadic *BRCA1*-associated breast cancers are often triple-negative and express basal markers [5], such as keratin 14 (K14) and K5.

BRCA1 is involved in the maintenance of genomic integrity and mainly relies on its central role in protein complexes that are required for the repair of double-strand breaks (DSB) and stalled replication forks [6]. *BRCA1* mutation carriers are at a higher risk of developing breast, ovarian, prostate, and other types of cancer. Furthermore, breast cancers with *BRCA1* mutations have earlier onset, more aggressive behavior, and a higher risk of recurrence [7]. Several functional partners of *BRCA1* have been described, contributing to better characterization of *BRCA1*'s role in DSBs' repair and its significance in breast carcinogenesis [1, 8–10].

DSBs are the most deleterious breaks in the genome [11, 12]. There are two main pathways for DNA DSB repair, homology-

directed repair (HDR) and non-homologous end-joining (NHEJ). HDR is an error-free approach, as the break is fixed by homology with the adjacent sister chromatid. However, this pathway is limited to the S/G2 phase of the cell cycle, where chromosomes are duplicated into two sister chromatids. On the other hand, the NHEJ repair joins the two ends of a DSB directly, making it more error-prone, yet available for use throughout the entire cell cycle [13]. These pathways largely operate in complementary ways when repairing DSBs [14].

DSB repair pathway choice is tightly regulated and has been linked to cancer progression [11, 15, 16]. It has been proposed that during the S phase, when *BRCA1* becomes more abundant, it forms a complex with CtIP, displacing RIF1/53BP1. Under these circumstances, *BRCA1* binds the MRN complex, which triggers end resection. It is only then that RAD51 filaments on 3' single strands are formed by *BRCA2* and followed by strand invasion into homologous DNA [7]. In the absence of functional *BRCA1*, cells experience defects in HDR and are forced to rely on alternative DNA repair mechanisms. Such alteration can potentially lead to genomic instability, further increasing the risk of developing breast cancer [10, 17–21]. It should be noted that many critical factors other than *BRCA1* including helicases (BLM) and nucleases (MRE11, EXO1, and DNA2) have been implicated in end resection however, others such as CtIP, for example, has been argued to have indispensable roles in promoting resection [22] hence highlighting the complexity of HDR regulation and the importance of in-depth understanding of its molecular basis.

¹The Concern Foundation Laboratories, The Lautenberg Center for Immunology and Cancer Research, Department of Immunology and Cancer Research-IMRIC, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. ²Department of Pathology, Hadassah University Hospital, Jerusalem, Israel. ³Cyprus Cancer Research Institute (CCRI), Nicosia, Cyprus. ⁴These authors contributed equally: Tirza Bidany-Mizrahi, Aya Shweiki. ✉email: ramiaq@mail.huji.ac.il

Received: 29 November 2023 Revised: 7 February 2024 Accepted: 20 February 2024

Published online: 18 March 2024

WW domain-containing oxidoreductase (*WWOX*) encodes a 46-kDa tumor suppressor that is commonly inactivated in TNBC [23]. *WWOX*, as an adapter protein, has two WW domains, which mediate its interaction with proline-rich motifs-containing proteins [24]. Through physical interaction, *WWOX* has been shown to modulate and regulate function of a number of key breast cancer relevant proteins including ErbB4, AP2, p53, c-JUN, JNK1, DVL and MERIT40 [18, 24–33]. Anti-tumor activity of *WWOX* was also reported using mouse models as conditional deletion of *Wwox* in *C3H:MMTV-Cre* mice leads to spontaneous basal-like mammary tumor development exhibiting p53 inactivation [27, 28]. Whether *WWOX* cooperates with *BRCA1* to suppress BLBCs and TNBCs is unknown.

An emerging and central function of *WWOX* that has been recently reported by several research groups is its direct role in the DNA damage response (DDR) and its involvement in DNA repair [18, 34]. We previously reported that *WWOX* enhances efficient repair of DSBs and DDR via interaction and regulation of ATM, a major DNA damage checkpoint protein [35, 36] as well as repair of single strand breaks (SSB) via activation of ATR [37]. More recently, *WWOX* binding with *BRCA1*, through the WW1 domain, was revealed. This interaction disrupts *BRCA1* binding to the MRN complex, causing less DNA end resection, hence redirecting the cell to repair DSBs via NHEJ pathway rather than HDR [17, 38, 39]. In other words, *WWOX* expression shifts DSB repair from HDR to NHEJ. However, the consequence of *WWOX-BRCA1* association and its loss have not been demonstrated *in vivo* using mouse models.

Since both *BRCA1* and *WWOX* are commonly inactivated in TNBC and are involved in DNA repair, we set to test whether inactivation of both proteins would affect mammary tumorigenesis *in vivo*. Furthermore, we tested the effect of *WWOX* expression on DNA DSB repair pathway choice when *BRCA1* is either wild-type or mutant in human TNBC cell lines. Our findings demonstrate a functional interaction between *WWOX* and *BRCA1*, affecting DSB repair pathway choice and regulating mammary tumorigenesis.

RESULTS

Combined targeted loss of *Wwox* and *Brca1* in *K14+* cells result in basal-like mammary tumors *in vivo*

In a previous work, we observed that conditional deletion of *Wwox* in *C3H:MMTV-Cre* mice resulted in the development of basal-like mammary tumors [27, 28]. The majority of those mice developed tumors and display inactivation or downregulation of p53 [27, 28]. Given that *WWOX* and *BRCA1* have been implicated in BLBC/TNBC and previously reported as interacting partners [17, 38, 39], we tested whether their targeted loss synergizes to affect mammary tumorigenesis *in vivo*. For this reason, we crossed the *K14-Cre* transgenic line with *Brca1* exon 11 flanked flox mice (referred to as *Brca1^{f/f}*), to generate a conditional mutated mouse for *Brca1* in mammary basal cells (Fig. 1A); validation of transgene manipulation is shown in Supplementary Fig. 1. For the sake of simplicity in terminology, we referred to progeny of *K14-Cre;Brca1^{f/f}* mice as *Brca1* KO. In this mouse model, mammary tumors only arise at low frequency and with very long latency, unless additional mutations in genes such as *Trp53* are present [8]. Indeed, consistent with published data, *K14-Cre;Brca1^{f/f}* female mice did not give rise to mammary tumors until 800 days of age (Fig. 1B). On the other hand, *Wwox* ablation in mixed B6-129 genetic background also didn't result in mammary tumor formation, consistent with previously published data [40, 41]. We next explored whether ablation of tumor suppressor *Wwox* can enhance mammary tumor formation in *K14-Cre;Brca1^{f/f}* mice. As expected, all *K14-Cre;Brca1^{f/f};Wwox^{f/f}* female mice developed basal-like mammary tumors with a median of 495 days (Fig. 1B). Additional depletion of one *Trp53* allele (*Trp53^{+/-}*) in the *K14-Cre;Brca1^{f/f};Wwox^{f/f}* mice reduced the median

of tumor development to 268 days (Fig. 1B), without affecting tumor morphology (Fig. 1C). Both *K14-Cre;Brca1^{f/f};Wwox^{f/f}* and *K14-Cre;Brca1^{f/f};Wwox^{f/f};Trp53^{+/-}* mammary tumors exhibited a basal-like morphology with occasional expression of K14 [42] and lack of ER expression (Fig. 1C), suggesting a worse prognosis recapitulating human BLBC/TNBC. Although normal mammary epithelium of these two mouse models expressed *WWOX* in most cells, conditional ablation of the indicated genes was enough for tumor development (Fig. 1C, Supplementary Fig 1). This is likely due to the mosaic Cre expression in this model where only 5–30% of mammary-gland epithelial cells express Cre [9] (Fig. 1C). The mammary tumors developed in these mice were indeed negative for *WWOX* expression (Fig. 1C). These results imply that *WWOX* has an important role in protecting against development of mammary tumors in which *Brca1* deficiency is involved.

K14-Cre;Brca1^{f/f};Wwox^{f/f} mice mammary epithelia express less NHEJ and more HDR markers as compared to *K14-Cre;Brca1^{f/f}*

Given the effect of combined deletion of *Wwox* and *Brca1* on mammary tumor formation and the known effect of *WWOX-BRCA1* interaction on DNA repair pathway choice *in vitro* [17, 38, 39], we next set to examine which DSB repair pathway is favored in tumors of *K14-Cre;Brca1^{f/f};Wwox^{f/f}* mice. To test this *in vivo*, immunostaining of p53-binding protein 1 (53BP1), a NHEJ repair marker, RAD51, a surrogate marker for HDR, and γH2AX, marking DSBs, was performed and quantified as detailed in the Methods sections. Mammary tumors from *K14-Cre;Brca1^{f/f};Wwox^{f/f}* and *K14-Cre;Brca1^{f/f};Wwox^{f/f};Trp53^{+/-}* mice exhibited elevated number of 53BP1, RAD51 and γH2AX foci per nuclei compared to their normal mammary (Fig. 2A, B and Supplementary Fig. 1). We did not observe a significant difference in these DNA damage marker's foci number between the two mouse models; neither in the mammary tumors nor in the normal mammary epithelium. These results suggest an intact DDR signaling in these tumors and that the DSB repair pathway choice was not affected upon depleting one *Trp53* allele in *K14-Cre;Brca1^{f/f};Wwox^{f/f}* tumors.

We next compared the normal mammary tissue of *Brca1^{f/f}* mice to those of *K14-Cre;Brca1^{f/f};Wwox^{f/f}* and *K14-Cre;Brca1^{f/f};Wwox^{f/f};Trp53^{+/-}* mice and found a substantial decrease in foci of the NHEJ marker 53BP1, in the normal mammary tissue lacking *Wwox* (Fig. 2A). On the other hand, when comparing RAD51 foci between the genotypes, we observed that loss of *WWOX* led to more abundant foci in the normal mammary cells (Fig. 2B). We also detected a slight increase in the RAD51 foci per nuclei in mammary epithelia of *K14-Cre;Brca1^{f/f}* mice compared to WT, likely suggesting impaired HDR repair (lacking *BRCA1*), or other RAD51-dependent repair mechanisms. These results correspond with previous *in vitro* findings [17, 38, 39], demonstrating that *WWOX*'s presence directs the DSB repair towards NHEJ, while its depletion results in compromised NHEJ repair and more HDR, even in the absence of *BRCA1*.

WWOX overexpression in *BRCA1* wild-type TNBC cells is associated with elevated NHEJ

The preceding results suggest that *Brca1* and *Wwox* cooperate *in vivo* to regulate DSB repair. To learn more about the role of *WWOX* and *BRCA1* in immediate response to DSB repair of human TNBC, we used MDA-MB-231 and MDA-MB-436 cell lines. MDA-MB-231 harbors *BRCA1* WT with low protein expression levels of *WWOX*, while MDA-MB-436 carries a 5396 +1 G > A mutation in the splice donor site of exon 20 of *BRCA1* [43] and express low protein levels of *WWOX*, as well. Using the recently developed SeeSaw Reporter 2.0 [44], we tested HDR and NHEJ repair outcome in these human TNBC cells *in vitro*. In this system, a double-strand break is generated by *ISceI* which can be alternatively repaired by homology-independent or -dependent




Fig. 1 Combined loss of *Wwox* and *Brca1* results in basal-like mammary tumors in vivo. **A** The *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl} Trp53^{+/fl}* mice transgenic mouse model. *K14-Cre* conditionally expressed in the basal mammary epithelia, and basal epidermis. **B** Tumor free survival curve of *K14-Cre; Brca1^{fl/fl}* ($n = 6$), *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl}* ($n = 6$) and *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl} Trp53^{+/fl}* ($n = 10$) mice. Solid color- basal-like mammary tumor, yellow- cutaneous squamous cell carcinoma. Statistical significance calculated by Log-rank (Mantel-Cox) test. **C** H&E stain and IHC stain (WWOX, K14, ER) of normal mammary and mammary tumors from *K14-Cre; Brca1^{fl/fl}*, *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl}* and *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl} Trp53^{+/fl}* mice. 40X. Scale- 200 μ m.

mechanisms, leading to the accumulation of distinct fluorescent protein; RFP (red) for HDR and GFP (green) for NHEJ repair. Expression of the system's endonuclease, *IScel*, is tracked by BFP [42]. Twenty-four hours after electroporation of the SeeSaw reporter into the two human TNBC cell lines, *IScel* together with *WWOX* or *EV* were introduced and 48 h later cells were analyzed via flow cytometry (Fig. 3A). The levels of *WWOX* were detected by western blot from lysates made of the same cells that were

analyzed via flow cytometry (Fig. 3B). In MDA-MB-231 cells, *IScel + WWOX* overexpressing (OE) cells exhibited a significant elevation in NHEJ repair (GFP+ cells) compared to *IScel + EV* cells, as expected, due to *WWOX*'s role in NHEJ repair (Fig. 3C, D- left panels).

Surprisingly, MDA-MB-436 cells expressing *WWOX* didn't display any significant change in the DSB repair pathways as compared to control (Fig. 3C, D- right panels). In both cell lines, no significant




Fig. 2 Combined loss of Wwox and Brca1 redirects the DSB repair to NHEJ in vivo. A Left- Endogenous NHEJ DSB repair marked by 53BP1 foci in normal mammary or mammary tumors from: K14-Cre;WT ($n = 3$), K14-Cre;Brca1^{f/f} ($n = 4$), K14-Cre;Brca1^{f/f}Wwox^{f/f} ($n = 3$) and K14-Cre;Brca1^{f/f}Wwox^{f/f}Trp53^{s/s} ($n = 8$) mice. Arrow heads marking the foci. Merge- 160X scale- 10 μ m, 750X scale- 20 μ m. Right- quantification of 53BP1 foci per nuclei, three 40x fields were quantified from each mouse. Statistical analysis by t-test, P value < 0.05, error bars representing SEM. P value between normal and mammary tumor- not significant. **B** Left- Endogenous HDR DSB repair marked by RAD51 foci in normal mammary or mammary tumors from: K14-Cre;WT ($n = 3$), K14-Cre;Brca1^{f/f} ($n = 4$), K14-Cre;Brca1^{f/f}Wwox^{f/f} ($n = 3$) and K14-Cre;Brca1^{f/f}Wwox^{f/f}Trp53^{s/s} ($n = 8$). Arrow heads marking the foci. Merge- 160X scale- 10 μ m, 750X scale- 20 μ m. Right- quantification of RAD51 foci per nuclei, three 40X fields were quantified from each mouse. Statistical analysis by t-test, P value < 0.05, error bars representing SEM. P value between normal and mammary tumor- not significant.

difference in the HDR levels was found between the *WWOX* overexpressing cells and their control. Altogether, these data imply that in human TNBC cells in vitro, *WWOX* shifted the DSB repair pathway toward NHEJ in the presence of *BRCA1*.

***WWOX* overexpression elevates NHEJ and reduces HDR in TNBC cells upon exposure to DNA damaging agents**

We next set to test how MDA-MB-231 and MDA-MB-436 cells expressing *WWOX* respond to DNA damage induction. Since platinum-based chemotherapies are often used in treatment of TNBC [45], we examined the effect of cisplatin treatment on empty vector (EV) or *WWOX* overexpressing (OE) TNBC cells. In addition, we examined sensitivity of these cells to ATM inhibitor (ATMi) as *WWOX* and ATM have been physically and functionally linked [34, 36]. To this end, MDA-MB-231 and MDA-MB-436 cells with EV and *WWOX* OE were treated with cisplatin (2 μ M), ATMi (15 μ M) or both for 24 hr, then immunostained for HDR and NHEJ DSB markers. We found that MDA-MB-436 cells treated with cisplatin and ATMi resulted in low levels of RAD51 foci, less than 5 foci per cell (Fig. 4B), likely due to their *BRCA1* status [46, 47]. More

interestingly, when comparing EV to *WWOX* OE cells, there was a significant reduction in the number of RAD51 foci per nuclei, especially in MDA-MB-231 cells (Fig. 4A-D). No synergistic effects were observed when using cisplatin and ATMi combined treatment. When normalizing the number of RAD51 foci per cell to their relative control without treatments, the same trends were preserved (Fig. 4D).

We next stained and quantified 53BP1 in MDA-MB-231 and MDA-MB-436 cells. In contrast to the trend observed in RAD51 foci, 53BP1 foci per cell were more abundant in the cells overexpressing *WWOX* compared to EV (Fig. 5A-F). The difference again was more prevalent in MDA-MB-231 cells, raising the possibility that the DSB repair pathway choice under different *WWOX* levels is partially *BRCA1*-dependent. Based on the observed difference between EV and OE in *BRCA1*-mutated MDA-MB-436 cells, it is plausible that *BRCA1* alone may not be the only player responsible for *WWOX*-mediated NHEJ, indicating the involvement of other factors or pathways in this repair mechanism. On another note, when comparing the number of 53BP1 foci in MDA-MB-231 cells treated with cisplatin or combined treatment with




Fig. 3 WWOX expression in BRCA1 WT TNBC cells elevates NHEJ as a response to direct DSB. **A** In vitro experimental design. MDA-MB-231 or MDA-MB-436 TNBC cell line were electroporated with the See-Saw Reporter 2.0 system plasmid, 24 h later, a lenti virus expressing the systems endonuclease, *lsceI*, was added in addition to lenti- *WWOX OE* or lenti- empty vector (*EV*). 48 h later the cells were analyzed via flow cytometry. **B** *WWOX* immunoblot of MDA-MB 231 and MDA-MB 436 with empty vector (*EV*) and *WWOX* overexpression (*OE*). HSP90 as a house keeping gene. **C** Flow-cytometry scatter plot of the MDA-MB-231 or MDA-MB-436 with lenti *EV* or lenti *WWOX OE* and the See-Saw system. Living cells, expressing *lsceI*, presenting HDR marked by RFP or NHEJ repair marked by GFP. **D** Quantification graph of the NHEJ and HDR cell populations percentages from the flow-cytometry results. three experimental repeats, statistical significance calculated by *t*-test, *P*-value < 0.01, error bars representing SEM.




Fig. 4 Loss of WWOX significantly reduces HDR repair, especially when BRCA1 is present. **A** HDR DSB repair marked by RAD51 foci in MDA-MB-231 TNBC cell line (sufficient BRCA1) with *EV* (left) or *WWOX OE* (right), with or without DNA damage agents (ATMi, cisplatin). **B** HDR DSB repair marked by RAD51 foci in MDA-MB-436 TNBC cell line (mutated *BRCA1*) with *EV* (left) or *WWOX OE* (right), with or without DNA damage agents (ATMi, Cisplatin). Scale: 120X-100uM, 600X-20uM. **C** Quantification of RAD51 foci per nuclei in MDA-MB-231 or 436 with *EV* or *WWOX OE*. At least 5 fields were quantified from each cell line and treatment. Statistical analysis by t-test, error bars representing SEM. **D** Fold change of RAD51 foci per nuclei treatment/ control of each of the cell lines. Statistical analysis by t-test, error bars representing SEM.

ATMi, we could see an increase in the latter treatment both in *EV* and *WWOX OE*. On the other hand, in MDA-MB-436 there was no significant difference between the two treatments. This implies that inhibition of ATM causes NHEJ stimulation in a BRCA1-related manner.

Additionally, we examined γH2AX foci and observed an increase in DSBs, as anticipated. Nevertheless, we did not detect any notable variations in the levels of damage among the distinct cell lines or genotypes (Fig. 5A-D), suggesting that the differences in the number of RAD51 and 53BP1 foci are not due to the number of DSBs. Altogether, our findings suggest that *WWOX* expression promotes DSB repair via the NHEJ pathway rather than HDR.

DISCUSSION

Loss of *BRCA1* and *WWOX* has been previously linked with TNBC development. Given that both tumor suppressors play a role in repairing DSBs, we aimed to test their functional interplay both *in vitro* and *in vivo*. We demonstrated that combined deletion of murine *Wwox* and *Brcal* in mammary gland epithelium resulted in accelerated BLBC-like tumors. Characterization of DSB repair in these tumors lacking *WWOX* and *BRCA1* expression revealed increased RAD51 and decreased 53BP1 foci relative to normal adjacent tissues suggesting that absence of *WWOX* redirects DSBs repair pathway away from NHEJ. These results were further confirmed *in vitro* using human TNBC cells and HDR/NHEJ reporter system (Fig. 6-graphical abstract).




Fig. 5 Loss of WWOX doesn't lead to more DNA damage but does increase NHEJ. A DNA DSB (γ H2AX) and NHEJ repair (53BP1) foci in MDA-MB-231 TNBC cell line with *EV* (left) or *WWOX OE* (right), with or without DNA damage agents (ATMi, cisplatin). **B** DNA DSB (γ H2AX) and NHEJ repair (53BP1) foci in MDA-MB-436 TNBC cell line (mutated *BRCA1*) with *EV* (left) or *WWOX OE* (right), with or without DNA damage agents (ATMi, cisplatin). Scale: 120 \times -100 μ M, 600 \times -20 μ M. Quantification of γ H2AX (**C**) and 53BP1 (**E**) foci per nuclei in MDA-MB-231 or 436 with *EV* or *WWOX OE*. At least 5 fields were quantified from each cell line and treatment, error bars representing SEM. Fold change of γ H2AX (**D**) and 53BP1 (**F**) foci per nuclei treatment/ control of each of the cell lines. Statistical analysis by t-test, error bars representing SEM.




Fig. 6 Graphical abstract summarizing the role of WWOX *in vivo* and *in vitro*. *K14-Cre; Brca1^{fl/fl} Wwox^{fl/fl}* mice harboring impaired HDR and insufficient NHEJ result in mammary tumor development, as compared to tumor-free *K14-Cre; Brca1^{fl/fl}* mice relying on NHEJ. MDA-MBA-231 cells with WT *BRCA1*, exhibit high levels of HDR, while 231-overexpressing *WWOX* shifts DSBs repair to NHEJ. MDA-MBA-436 with mutant *BRCA1*, exhibit low levels of HDR, while 436-overexpressing *WWOX* shifts DSBs repair to NHEJ mediated by unknown DDR player.

WWOX has been primarily mapped to fragile site FRA16D in breast cancer due to its common deletion and alteration [48]. The FRA16D locus is a chromosomal region on chromosome 16q23.2 that is prone to DNA breakage and rearrangements, particularly in cancer cells undergoing replication stress [34]. Several studies have shown that WWOX is frequently subjected to genetic alterations, such as deletions, mutations, and loss of expression, in various cancers, including breast cancer [27, 28, 49]. We and others have recently shown that gene products of common fragile sites can have direct roles in DDR [34, 36, 37, 50, 51]. In fact, WWOX expression is induced early upon DNA damage contributing to proper DDR signaling [36, 37]. Therefore, loss of WWOX makes cells more susceptible to genomic instability.

Loss or reduced expression of WWOX has been associated with breast cancer development and progression [23, 25, 52–58]. As a tumor suppressor gene and a scaffold protein, WWOX plays a crucial role in regulating multiple cellular processes, including cell growth, apoptosis, DNA repair, and maintenance of genomic stability [34]. WWOX inactivation can hence contribute to the disruption of these processes, promoting tumorigenesis in breast cancer. Recent genomic studies have identified germline biallelic aberrations of WWOX in patients with multiple primary cancers including breast cancer. Interestingly, co-occurrence of WWOX mutations has been observed with genetic variants in genes involved in DNA repair, such as *BRCA2*, *TP53*, *CHK2* and *RAD51* [59, 60].

We have shown previously that WWOX cooperates with p53 to antagonize mammary tumor formation [27, 59]. In human breast cancer, there is evidence of a correlation between nuclear *BRCA1* and WWOX expression [52]. However, a detailed study

investigating the expression of WWOX in various *BRCA1* variants and mutations doesn't yet exist. Our findings here show for the first time that in *K14-Cre* conditional murine model, combined deletion of *Wwox* and *Brca1* synergizes to accelerate mammary tumor formation *in vivo*. Individually, the loss of either *Wwox* or *Brca1* in the *K14-Cre* model may not be sufficient to initiate tumor formation. This implies that there is cooperation between WWOX and *BRCA1* in suppressing tumorigenesis. This also suggests that both WWOX and *BRCA1* play crucial roles in maintaining the normal function of cellular processes, such as DNA integrity, that prevent tumor development. When both genes are simultaneously deleted, there is a synergistic effect that impairs this integrity, leading to accelerated tumor development. The interaction between WWOX and *BRCA1* may involve shared or complementary functions in regulating key pathways involved in cell growth control, DNA repair, and maintenance of genomic stability. Loss of either gene alone may be compensated for by the remaining intact gene or by alternative pathways. However, the simultaneous loss of both genes likely disrupts these compensatory mechanisms, leading to an increased susceptibility to tumor formation. Deletion of one *p53* allele further accelerates tumor formation mediated by loss of *Wwox* and *Brca1*, further demonstrating the significance of this triad in breast cancer development.

How WWOX expression inhibits HDR is not well understood. Clear evidence proposed by our data suggests that WWOX expression favors NHEJ rather than HDR. A recent study has revealed that WWOX negatively regulates HDR activity in HeLa cells [18]. Taouis et al. have identified MERIT40 as a novel molecular partner of WWOX and demonstrated that the interaction between WWOX and MERIT40 hinders the ability of MERIT40 to bind to Tankyrase. Tankyrase plays a positive role in NHEJ by stabilizing the kinase DNA-PK. The inhibition of Tankyrase-MERIT40 interaction by WWOX suppresses the enhancing function of this complex in HDR, while facilitating the role of Tankyrase in NHEJ. In contrast, a previous paper by Abu-Odeh and colleagues, has shown that WWOX enhances HDR in U2OS cells [36]. We assume that the different cell lines and reporter systems as well as the cell-specific behaviors could contribute to the varying outcomes between this article and the current one. Our findings, both *in vivo* and *in vitro* are in alignment with a prior study conducted by Park et al. [17]. Their research revealed heightened RAD51 levels in WWOX-negative cells and established a link between the absence of WWOX and enhanced DNA end resection. This premature resection can lead to increased HDR before the S phase, potentially undermining the precision of HDR and contributing to mutagenic outcomes, genome instability and risk of tumorigenesis. Our mice with dual deficiencies in WWOX and *BRCA1* exhibit increased levels of RAD51, indicative of heightened HDR. However, unlike mice with *BRCA1* deficiency alone, the double knockout mice developed tumors. This observation implies that the double KO mice may indeed have elevated RAD51 levels and increased homology-directed repair, but its effectiveness appears compromised. Whether this previously discovered mechanism *in vitro* is also true for our *in vivo* system will still need to be answered. Our data reveal that in the absence of *BRCA1* and WWOX, RAD51 and 53BP1 foci are still detected. It is plausible that combined ablation of *Wwox* and *Brca1*, in our genetically engineered mice, results in impaired HDR and NHEJ. The presence of RAD51 in mammary cells with deletion of *Brca1*, or in human MDA-MB-436 cells with a loss of function mutation in *BRCA1*, can prove that RAD51 might participate in different pathways other than HDR. Indeed, RAD51 has been found to play a role in less efficient repair mechanisms of DSBs such as interstrand cross-link repair or break-induced replication [60–63] that can result in serious consequences for DNA integrity. Furthermore, RAD51 is found to be overexpressed in several types of cancer, and implicated in resistance to chemotherapy

[64–66], in contrast to the other components of the HDR pathway. It is possible that the non-canonical properties of RAD51 are manifested when BRCA1 is absent, together with the genomic instability that is enhanced upon absence of WWOX, causes extensive DNA damage, supporting cancer development, and resistance to treatments. Our data also revealed treatment resistance in human MDA-MB-231 and MDA-MB-436 cells lacking WWOX (not shown). Following ATM treatment, TNBC cells lacking WWOX express less sub G1 population in cell- cycle flow-cytometry compared to WWOX overexpressing counterparts (not shown).

Similarly, the persistence of 53BP1 foci in BRCA1 mutant cells indicates that the NHEJ pathway is still functional to some extent. While BRCA1 is not directly involved in NHEJ, it is possible that other proteins and factors can contribute to the recruitment and activation of 53BP1 in these cells. We acknowledge that while 53BP1 is commonly used as an indicator of NHEJ, it might not provide a direct measure of NHEJ activity. Nevertheless, there are several lines of evidence supporting the use of 53BP1 as a NHEJ marker [17, 67, 68]. For precise assessment of NHEJ, additional investigation will be required. Overall, the presence of RAD51 and 53BP1 foci in WWOX and BRCA1 mutant cells suggests a dynamic interplay between different DNA repair pathways and compensatory mechanisms. This highlights the complex nature of DNA repair and the ability of cells to utilize alternative pathways when the primary repair mechanisms are compromised.

In summary, our study revealed that WWOX and BRCA1 loss led to the development of basal-like mammary tumors and impaired DSB repair. WWOX promoted NHEJ repair in cells with wild-type BRCA1. Additionally, TNBC cells dependent on WWOX-mediated NHEJ repair showed increased sensitivity to DNA damaging agents. These findings suggest that relying solely on HDR for DSB repair may be insufficient in mammary cells, leading to tumorigenesis and DNA damage resistance. WWOX plays a crucial role in the choice of DSB repair pathway in mammary cells, highlighting its significance as a tumor suppressor in breast carcinogenesis.

METHODS

Mice

Brcal^{tm2Cxd}/Nci [*Brcal*^{Δ11}, Strain Number: 01XC8] mice were ordered from NCI Mouse Repository. These mice carry *LoxP* sites around exon 11 of *Brcal* (*Brcal*^{Δ11} or *Brcal*^{fl/fl}), which encodes 60% of the protein [69]. *Brcal*^{fl/fl} mice were bred with *K14-Cre*; For the sake of simplicity in terminology, we referred to progeny of *K14-Cre;Brcal*^{fl/fl} mice as *Brcal* KO. *Wwox*^{fl/fl} mice to generate double conditional knockout (DKO) mice: *K14-Cre;Brcal*^{fl/fl}; *Wwox*^{fl/fl} DKO mice were also bred with *Tp53*^{+/fl} to generate *K14-Cre;Brcal*^{fl/fl}; *Wwox*^{fl/fl}; *Tp53*^{+/fl}. Mammary tissues or tumors were fixed in 4% formaldehyde and processed for H&E staining and immunohistochemistry (IHC). Our mice were handled in the specific pathogen free (SPF) animal facilities of the Hebrew university according to the ethical standards approved by the Institutional Animal Care and Use Committee.

Cell culture

MDA-MB-231 (CVCL_0062) and MDA-MB-436 (CVCL_0623) cell lines were grown in DMEM (Gibco) supplemented with 10% FBS (Gibco), glutamine, and penicillin/streptomycin (Biological Industries). All cells were grown in 37 °C with 5% CO₂. Cells were routinely authenticated and confirmed as Mycoplasma-free, and cell aliquots from early passages were used. Stable clones for *Wwox* overexpression were produced using a lentiviral vector containing either empty vector (EV) or *WWOX* overexpression (*WWOX* OE). Clones were selected using 2 mg/mL G418 (Gibco 11811031).

Histology and Immunohistochemistry

Tissues were fixed with 4% formalin, then 70% ethanol and processed. Paraffin-embedded tissue sections were deparaffinized and rehydrated, then stained with H&E for histological observation and diagnosis. For IHC, paraffin-embedded tissues were deparaffinized, followed by antigen retrieval using 25 mM citrate buffer (pH 6) in a pressure cooker. Then the sections were left to cool for 25 min, followed by blocking of the

endogenous peroxidase with 3% H₂O₂ for 15 min. To reduce nonspecific binding of the primary antibody, tissues were blocked with blocking solution (CAS Block, Invitrogen, San Diego, CA), followed by incubation with the primary antibody overnight at 4 °C: Rb polyclonal anti WWOX [70] (1:8,000); Rb anti CK14 (ab181595, 1:2000); Rb anti ER (1:350, Sc-543); Rb anti p53 (1:400, NCLP53CM5p). Sections were washed 3 times with TBST and incubated with secondary HRP anti-rabbit IgG antibody for 30 min. After additional washes using TBST, the reaction was then performed using a DAB peroxidase kit (Vector Laboratories, SK-4100, Mowry Ave Newark, United State), followed by hematoxylin stain for 45 s as a counterstain.

Immunofluorescence

Tissues were fixed in 4% formalin, then 70% ethanol and processed. Paraffin-embedded tissue sections were deparaffinized and rehydrated. Antigen retrieval was performed in 25 mM sodium citrate buffer PH 6.0 using pressurized chamber for 2.5 min. The sections were then incubated with blocking buffer (5% goat serum+0.5% BSA in PBT) for 1 h to reduce nonspecific binding followed by incubation with the antibodies overnight at 4 °C: Rb anti γH2AX (1:200, #9718), Rb anti-RAD51 (1:200, GTX100469), Rb anti-53BP1 (1:200, ab36823), Rb anti BRCA1 (1:100, sc-646). Slides were subsequently washed with PBS, incubated with secondary anti-Rabbit Alexa fluor 647 (1:300, ab150079) for one hour, in addition to Hoechst nuclear counter stain. Finally, slides were mounted by Dako's Fluorescence Mounting Medium.

Cells were seeded on round slide coverslips in 12-well plates and treated with DMSO 1:1000, ATM 15 μM (KU55933, sigma), 2 μM cisplatin (Courtesy of Hadassah Hospital) or combined ATM 15 μM and 2 μM cisplatin; doses were based on previous literature [71, 72] and our own optimization. 24 hours later, cells were fixed in 4% PBS buffered formaldehyde and permeabilized with 0.05% Triton X-100 at room temperature. Cells were then incubated in blocking buffer (5% goat serum+0.5% BSA in PBT) for 1 hour, followed by primary antibodies overnight at 4 °C: mouse anti-γH2AX (1:1000, ab26350), Rb anti-RAD51 (1:200, GTX100469), Rb anti-53BP1 (1:200, ab36823). After PBS washes, slides were incubated with secondary antibodies- anti-Rabbit Alexa fluor 647 (1:300, ab150079) anti-Mouse Alexa fluor 488 (1:1000, A11029) for 1 hour in addition to Hoechst nuclear counter stain. Slides were mounted by Dako's Fluorescence Mounting Medium. For the DNA damage markers staining of the mice's normal mammary and tumors, at least four 40X fields were imaged, then quantified manually by counting the foci, and the nuclei. For the MDA-MB-231 and MDA-MB-436 cells immunofluorescence, the slides have been scanned by a digital slide scanner (3Dhistech); at least four 40X fields were selected and quantified by Qupath software [73] for the number of foci and nuclei.

Electroporation and Lenti-Transduction

For electroporation, NEON transfection system was used. Cells (5*10⁷ cells/ml) were washed with PBS then resuspended with resuspension buffer R together with 6 μg DNA from each plasmid. Cells were shocked using the electroporation device, then were seeded for 24 h in medium containing serum and supplements without antibiotics. For Lentiviral transduction, 1 ml of medium with suspended cells was infected with 1 ml of medium containing the relevant Lenti-Virus + 1:1000 polybrene. To create stable clones the cells were later selected using 2 mg/mL G418 (Gibco 11811031).

SeeSaw reporter (SSR 2.0)

Cells were electroporated with the See-Saw Repoter 2.0 system plasmid, 24 h later, a lenti virus expressing the systems endonuclease, *Isce1*, was added in addition to lenti- *Wwox* overexpression (*Wwox* OE) or lenti- empty vector (EV). A double-strand break is created *Isce1* endonuclease and can be alternatively repaired by homology-independent or -dependent mechanisms, leading to the accumulation of distinct fluorescent proteins; RFP (red) for HDR and GFP (green) for NHEJ repair. Expression of the system's endonuclease, *Isce1*, is reported by BFP [45]. 48 h after addition of the lenti-viruses the cells were analyzed via flow cytometry.

Flow cytometry

Cells were trypsinized and centrifuged, then their pellets were fixed using 1 ml of methanol-PBS (9:1) overnight in –20 °C. Cells were then centrifuged and resuspended with FACS buffer (PBS, 2% fetal bovine serum, 1 mM EDTA, 0.1% sodium azide) and filtered by mesh. Flow cytometry readings were done by Beckman Coulter CytoFlex. GFP was excited using a 488 nm laser and acquired with a 525-40 filter, RFP was

excited using a 561 nm laser and acquired with a 610–20 filter, BFP was excited on a 405 nm laser and acquired with a 450–50 filter.

DATA AVAILABILITY

Raw data are available upon reasonable request.

REFERENCES

- Christou CM, Kyriacou K. BRCA1 and Its Network of Interacting Partners. *Biol. (Basel)*. 2013;2:40. Jan 2
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J. Clin.* 2018;68:7–30. Jan 1
- Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. *Ann Oncol Off J Eur Soc Med Oncol.* 2012;23 Suppl 6(SUPPL. 6).
- Orr KS, Savage KI. The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes — Implications for DNA Damage Response, DNA Repair and Cancer Therapy. *Adv DNA Repair.* 2015 Nov 18
- Akshata Desai KA. Triple Negative Breast Cancer – An Overview. *Hered Genet.* 2012;2013 (Suppl 2).
- Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat. Rev. Cancer.* 2011;12:68–78. Jan
- Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. *101146/annurev-cancerbio-030617-050502.* 2018 Mar 5;2:313–36.
- Liu X, Holstege H, Van Der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. *Proc. Natl Acad. Sci. USA.* 2007;104:12111–6. Jul 17
- Jonkers J, Meuwissen R, Van der Gulden H, Peterse H, Van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. *Nat. Genet.* 2001;29:418–25.
- Wiegmans AP, Al-Ejeh F, Chee N, Yap PY, Gorski JJ, Da Silva L, et al. Rad51 supports triple negative breast cancer metastasis. *Oncotarget* 2014;5:3261.
- Chapman JR, Taylor MRG, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. *Mol. Cell.* 2012;47:497–510. Aug 24
- Oster S, Aqeilan RI. Programmed DNA Damage and Physiological DSBs: Mapping, Biological Significance and Perturbations in Disease States. *Cells* 2020;2020:9;1870. Aug 10 9 1870
- Liu C, Srihari S, Cao KAL, Chenevix-Trench G, Simpson PT, Ragan MA, et al. A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. *Nucleic Acids Res.* 2014;42:6106. Jun 6
- Essers J, Van Steeg H, De Wit J, Swagemakers SMA, Vermeij M, Hoeijmakers JHH, et al. Homologous and non-homologous recombination differentially affect DNA damage repair in mice. *EMBO J.* 2000;19:1703–10. Apr 3
- Ceccaldi R, Rondinelli B, D'Andrea AD. Repair Pathway Choices and Consequences at the Double-Strand Break. *Trends Cell Biol.* 2016;26:52–64. Jan 1
- Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. *Cell Res* 2008 181. 2007;18:134–47. Dec 24
- Park D, Gharghabi M, Schrock MS, Plow R, Druck T, Yungvirt C, et al. Interaction of Wwox with Brca1 and associated complex proteins prevents premature resection at double-strand breaks and aberrant homologous recombination. *DNA Repair (Amst.)* 2022;110:103264. Feb 1
- Taouis K, Vacher S, Guirouilh-Barbat J, Camonis J, Formstecher E, Popova T, et al. WWOX binds MERIT40 and modulates its function in homologous recombination, implications in breast cancer. *Cancer Gene Ther.* 2023. 2023;29:1–12. May
- Scully R, Panday A, Elango R, Willis NA. DNA double-strand break repair-pathway choice in somatic mammalian cells. *Nat. Rev. Mol. Cell Biol.* 2019;20:698–714. Nov 1
- Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. *Cold Spring Harb. Perspect. Biol.* 2015;7:a016600.
- Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nat. Rev. Cancer* 2012 129. 2012;12:587–98. Aug 24
- Polato F, Callen E, Wong N, Faryabi R, Bunting S, Chen HT, et al. CtIP-mediated resection is essential for viability and can operate independently of BRCA1. *J. Exp. Med.* 2014;211:1027–36.
- Khawaled S, Suh SS, Abdeen SK, Monin J, Distefano R, Nigita G, et al. WWOX inhibits metastasis of triple-negative breast cancer cells via modulation of miRNAs. *Cancer Res.* 2019;79:1784–98.
- Tanna M, Aqeilan RI. Modeling WWOX Loss of Function in vivo: What Have We Learned? *Front Oncol.* 2018;8:420. Oct 10
- Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, et al. Association of Wwox with ErbB4 in Breast Cancer. *Cancer Res.* 2007;67:9330–6. Oct 1
- Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, et al. WW Domain-Containing Proteins, WWOX and YAP, Compete for Interaction with ErbB-4 and Modulate Its Transcriptional Function. *Cancer Res.* 2005;65:6764–72. Aug 1
- Abdeen SK, Ben-David U, Shweiki A, Maly B, Aqeilan RI. Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer. *Cell Death Dis.* 2018;9:832.
- Abdeen SK, Aqeilan RI. Decoding the link between WWOX and p53 in aggressive breast cancer. *Cell Cycle Taylor Francis Inc.* 2019;18:1177–86. p
- Guler G, Huebner K, Hımmetoglu C, Jimenez RE, Costinean S, Volinia S, et al. Fragile histidine triad protein, WW domain-containing oxidoreductase protein wwox, and activator protein 2y expression levels correlate with basal phenotype in breast cancer. *Cancer* 2009;115:899–908. Feb 15
- Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM, et al. Physical Association with WWOX Suppresses c-Jun Transcriptional Activity. *Cancer Res.* 2006;66:11585–9. Dec 15
- Chang NS, Doherty J, Ensign A. JNK1 Physically Interacts with WW Domain-containing Oxidoreductase (WOX1) and Inhibits WOX1-mediated Apoptosis. *J. Biol. Chem.* 2003;278:9195–202. Mar 14
- Del Mare S, Salah Z, Aqeilan RI. WWOX: Its genomics, partners, and functions. *J. Cell Biochem.* 2009;108:737–45. Nov 1
- Bouteille N, Driouch K, Hage PE, Sin S, Formstecher E, Camonis J, et al. Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. *Oncogene* 2009;28:2569–80. Jul 16
- Aqeilan RI, Abu-Remaileh M, Abu-Odeh M. The common fragile site FRA16D gene product WWOX: Roles in tumor suppression and genomic stability. *Cell Mol. Life Sci.* 2014;71:4589–99. Oct 5
- Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat. Rev. Mol. Cell Biol.* 2013 144. 2013;14:197–210. Mar 13
- Abu-Odeh M, Salah Z, Herbel C, Hofmann TG, Aqeilan RI. WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. *Proc. Natl Acad. Sci. USA.* 2014;111:E4716–25.
- Abu-Odeh M, Hereema NA, Aqeilan RI. WWOX modulates the ATR-mediated DNA damage checkpoint response. *Oncotarget* 2016;7:4344–55.
- Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH, et al. Wwox-Brca1 interaction: role in DNA repair pathway choice. *Oncogene* 2017;36:2215–27. Apr 20
- Park D, Gharghabi M, Reczek CR, Plow R, Yungvirt C, Aldaz CM, et al. Wwox Binding to the Murine Brca1-BRCT Domain Regulates Timing of Brip1 and CtIP Phospho-Protein Interactions with This Domain at DNA Double-Strand Breaks, and Repair Pathway Choice. *Int. J. Mol. Sci.* 2022;23:3729.
- Abdeen SK, Salah Z, Khawaled S, Aqeilan RI. Characterization of WWOX inactivation in murine mammary gland development. *J. Cell Physiol.* 2013;228:1391–6. Jul
- Ferguson BW, Gao X, Kil H, Lee J, Benavides F, Abba MC, et al. Conditional Wwox deletion in mouse mammary gland by means of two Cre recombinase approaches. *PLoS One.* 2012;7:e36618. May 4
- Laakso M, Loman N, Borg Å, Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. *Mod. Pathol.* 2005 1810. 2005;18:1321–8. Jul 1
- Elstrodt F, Hollestelle A, Nagel JHA, Gorin M, Wasielewski M, Van Den Ouwerland A, et al. BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants. *Cancer Res.* 2006;66:41–5. Jan 1
- Gomez-Cabello D, Jimeno S, Fernández-Ávila MJ, Huertas P. New Tools to Study DNA Double-Strand Break Repair Pathway Choice. *PLoS One.* 2013;8:e77206. Oct 14
- Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur. J. Pharm.* 2014;740:364. Oct 10
- Nacson J, Krais JJ, Bernhard AJ, Clausen E, Feng W, Wang Y, et al. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. *Cell Rep.* 2018;24:3513–e7. Sep 25
- Wang Y, Bernhard AJ, Nacson J, Krais JJ, Tan YF, Nicolas E, et al. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. *Nat. Commun.* 2019 10. 2019;10:1–12. Dec 11
- Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: tumor suppression through specific protein interactions. *Future Oncol. (Lond., Engl.)*. Future Oncol. 2010;6:249–59. p
- Gardenswartz A, Aqeilan RI. WW domain-containing oxidoreductase's role in myriad cancers: clinical significance and future implications. *Exp. Biol. Med. (Maywood)*. 2014;239:253–63.
- Waters CE, Saldivar JC, Hosseini SA, Huebner K. The FHIT gene product: tumor suppressor and genome "caretaker". *Cell Mol. Life Sci.* 2014;71:4577–87. Oct 5

51. Karras JR, Paisie CA, Huebner K. Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis. *Cancers (Basel)*. 2014;6:1208–19.
52. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, et al. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. *Breast Cancer Res Treat*. 2011;129:421–32. Sep
53. Chang R, Song L, Xu Y, Wu Y, Dai C, Wang X, et al. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis. *Nat. Commun.* 2018;9:3486.
54. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K. Wwox and Ap2gamma expression levels predict tamoxifen response. *Clin. Cancer Res.* 2007;13:6115–21. Oct 15
55. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, et al. Concordance among Gene-Expression-Based Predictors for Breast Cancer. *N. Engl. J. Med.* 2006;355:560–9. Aug 10
56. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. *Cancer* 2004;100:1605–14. Apr 15
57. Lee N-Y, Hum M, Zihara S, Wang L, Myint MK, Lim DW-T, et al. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer. *Hum. Genomics.* 2023;17:66. Jul 17
58. Xu A, Wang W, Nie J, Lui VVY, Hong B, Lin W. Germline mutation and aberrant transcripts of WWOX in a syndrome with multiple primary tumors. *J. Pathol.* 2019;249:19–25. Sep 1
59. Abdeen SK, Salah Z, Maly B, Smith Y, Tufail R, Abu-Odeh M, et al. Wwox inactivation enhances mammary tumorigenesis. *Oncogene* 2011;30:3900–6. Sep 8
60. Amunugama R, Willcox S, Wu RA, Abdullah UB, El-Sagheer AH, Brown T, et al. Replication Fork Reversal during DNA Interstrand Crosslink Repair Requires CMG Unloading. *Cell Rep.* 2018;23:3419–28. Jun 19
61. Long DT, Räschle M, Joukov V, Walter JC. Mechanism of RAD51-dependent DNA interstrand cross-link repair. *Science* 2011;333:84–7. Jul 1
62. Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. *Science* 2014;343:88–91.
63. Wassing IE, Esashi F. RAD51: Beyond the break. *Semin Cell Dev. Biol.* 2021;113:38. May 1
64. Liu H, Weng J. A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction. *Front Oncol.* 2022;12:858756. Mar 10
65. Zhang X, Ma N, Yao W, Li S, Ren Z. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. *Cancer Cell Int.* 2019;19:1–11. Dec 27
66. Klein HL. The Consequences of Rad51 Overexpression for Normal and Tumor Cells. *DNA Repair (Amst.)*. 2008;7:686. May 5
67. Callen E, Di Virgilio M, Kruhlak MJ, Nieto-Soler M, Wong N, Chen HT, et al. 53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions. *Cell* 2013;153:1266–80. Jun 6
68. Jachimowicz RD, Beleggia F, Isensee J, Velpula BB, Goergens J, Bustos MA, et al. UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. *Cell* 2019;176:505–e22. Jan 24
69. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. *Nat. Genet.* 2001;28:266–71.
70. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. *Proc. Natl Acad. Sci. USA*. 2004;101:4401–6.
71. Jiang Y, Ji F, Liu Y, He M, Zhang Z, Yang J, et al. Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. *Oncol. Rep.* 2017;38:3668–76. Dec 1
72. Zhang M, Qu J, Gao Z, Qi Q, Yin H, Zhu L, et al. Timosaponin AIII Induces G2/M Arrest and Apoptosis in Breast Cancer by Activating the ATM/Chk2 and p38 MAPK Signaling Pathways. *Front Pharm.* 2021;11:601468. Jan 15
73. Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. *Sci. Rep.* 2017;71. 2017;7:1–7. Dec 4

ACKNOWLEDGEMENTS

We are grateful to Dr. Suhaib Abdeen, for the establishment of the mice colony, Shani Mistriel-Zerbib for FACS technical help and assistance and Sara Oster for the critical reading of the manuscript.

AUTHOR CONTRIBUTIONS

TBM conducted most of the experiments, analyzed, quantified and interpreted data, wrote and edited the manuscript; AS was in charge of the mice colony, harvesting the tumors and the initial idea; KM conducted some of the experiments, quantified the results, preformed the statistical analysis, helped with the design of the images, writing and editing the manuscript; LA-T planned, preformed and quantified the See-Saw experiment; BM gave a pathological diagnosis of the mice mammary tumors; RIA directed the experimental design, reviewed and edited the manuscript. All authors reviewed the manuscript and approved the content.

FUNDING

The research work was funded by the European Research Council (ERC) [No. 682118] and Israel Science Foundation (ISF) [No. 1056/21].

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL

Our mice were handled in the specific pathogen free (SPF) animal facilities of the Hebrew university according to the ethical standards approved by the Institutional Animal Care and Use Committee.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41420-024-01878-8>.

Correspondence and requests for materials should be addressed to Rami I. Aqeilan.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024